Opinion

Video

Latest Advances and Therapies for HER2+ NSCLC

Key Takeaways

  • Emerging HER2-directed therapies show promise in NSCLC, with significant results from SOHO-01, inetetamab/pyrotinib, and Beamion LUNG-1 studies.
  • These studies indicate a potential shift in the treatment landscape, offering new options for patients with HER2 mutations in NSCLC.
SHOW MORE

Panelists discuss how recent clinical trial results for emerging HER2-directed therapies, including findings from the SOHO-01 study, inetetamab/pyrotinib combination study, and Beamion LUNG-1, are shaping the future landscape of NSCLC treatment, while also highlighting other noteworthy developments presented at this year’s World Conference on Lung Cancer.

Video content above is prompted by the following:

  • Several HER2-directed therapies are currently in development. Could you discuss the recent clinical trial results for emerging agents, such as those from the SOHO-01 study, the inetetamab/pyrotinibcombination study, and the Beamion LUNG-1 study, and what implications these findings might have for the future landscape of HER2-directed therapies in NSCLC?
  • (Heymach) What other notable data from this year’s World Conference on Lung Cancer are you most excited about?
Related Videos
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
4 KOLs are featured in this series
Surbhi Sidana, MD, MBBS
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo